cmc considerations for biotechnology product development: a regulatory perspective
Published 3 months ago • 3K plays • Length 56:31Download video MP4
Download video MP3
Similar videos
-
29:42
cmc considerations for car t cell product development
-
27:10
overview of post-approval chemistry, manufacture, and controls (cmc) changes to an nda - redi 2020
-
36:49
webinar: overview of cmc biotechnology webinar - dr nadine ritter
-
1:20:20
chemistry, manufacturing controls (cmc) in an investigational new drug (ind) (7/14) redi 2017
-
30:29
cmc considerations for oncolytic viral product development
-
15:58
quality considerations for transition biological products (32of33) quality – oct. 16-17, 2019
-
1:02:19
chemistry and manufacturing requirements for early clinical development: what’s in there? prove it.
-
19:31
an overview of pre-license inspections for biotech products (5/15) global quality
-
6:04:12
redi annual conference 2024: cber (biologics) innovation in medical product development (day 1 of 2)
-
1:59:15
2021 fda science forum – session #4 - product development and manufacturing
-
57:58
common cmc (quality) issues and how to avoid them part i (12of16) generic drugs forum
-
0:21
20. if you have a complaint about a product regulated by the fda the agency wants to👂about it.
-
38:56
role of the product jurisdiction team in the medical product development process
-
16:56
global generic drug landscape
-
0:12
⏳loading our new #fdafacts series on products that are (and aren’t) fda approved.
-
1:43:09
fda nanoday symposium 2022 welcome, keynote and session 1
-
5:03:46
2023 fda science forum - day 1: sessions 2 and 4
-
1:10:48
cmc - nda requirements and common pitfalls of blas (14of15) redi – may 29-30, 2019
-
10:30
vol 41: implications of recent regulatory changes on cmc drug development: a look ahead